查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
微生物組治療市場規模和預測、全球和地區佔有率、趨勢和成長機會分析（按類型、應用、最終用戶和地理位置）
市場調查報告書
商品編碼
1389658

微生物組治療市場規模和預測、全球和地區佔有率、趨勢和成長機會分析（按類型、應用、最終用戶和地理位置）

Microbiome Therapeutics Market Size and Forecasts, Global and Regional Share, Trends, and Growth Opportunity Analysis By Type, Application, End User, and Geography
出版日期: | 出版商: The Insight Partners | 英文 160 Pages | 訂單完成後即時交付

價格

微生物組治療市場預計將從2022年的3.7592億美元成長到2030年的8.1338億美元；預計2022年至2030年CAGR為10.1%。

人體微生物組包括人體內部和周圍發現的所有微生物及其相關代謝物/產物。技術進步使得研究人類腸道微生物組在維持健康和疾病方面的多效作用成為可能。由於微生物在人類健康中具有廣泛的潛力，因此它們具有用作疾病管理療法的巨大潛力。微生物組療法有望治療任何嚴重類型的疾病，並透過克服各種環境中的人際變異性和穩定性等關鍵問題，成為實現個人化治療目標的潛在來源。糞便微生物移植（FMT）或依賴外源性微生物施用的益生菌等策略可用於治療與菌叢失調相關的疾病。

腸道微生物群在維持人類健康方面的潛力推動微生物組治療市場的成長

微生物組療法旨在透過使用噬菌體、細菌素、抗生素、天然或合成細菌，或減法或調節治療來改變腸道微生物組。透過提供個人化、協調、可靠和持久的治療，該策略可以克服傳統療法的限制。全球治療市場已展現出其巨大的經濟潛力。研究表明，使用微生物組療法治療發炎性腸道疾病、肥胖甚至精神健康障礙等疾病具有良好的效果。正在進行的研究也正在探索以微生物組為基礎的干涉措施在癌症治療、糖尿病管理和心血管健康領域的潛力。此外，胃腸道疾病的發生率隨著年齡的成長而增加，胃腸道聯盟2021年2月的資料估計，近2,000萬美國人患有慢性消化系統疾病，每年有超過6,200萬美國人被診斷患有胃腸道疾病。國際胃腸道疾病基金會（IFFGD）發布的統計數據顯示，GERD盛行率在北美為18%至28%，在南美為23%，在歐洲為9-26%。因此，在未來幾年，胃腸道疾病發生頻率的增加將推動市場擴張。

透過了解微生物組與疾病發展之間的複雜關係，科學家正在開發針對問題根源的個人化治療方法，而不僅僅是控制症狀。隨著知識的擴展和技術的進步，微生物組療法有可能成為現代醫學的基石，為改善受一系列疾病影響的個人的健康結果帶來希望。

人們越來越認知到微生物組在人類健康和疾病中的重要性，這鼓勵了嚴格的研究和開發工作，以進一步了解人類微生物組並開發微生物組療法。它幫助開發了潛在的療法並確定了障礙。技術和研究工具的進步也促進了研發的成長。新一代定序和宏基因組分析可以對微生物組進行更全面、更詳細的研究。這些工具使研究人員能夠識別特定的微生物種類及其功能，並追蹤微生物組隨時間的變化。 FDA 等監管機構也支持微生物組治療領域的研發工作。 FDA 制定了 FMT 指南，並有興趣透過監管途徑推進該領域的發展，以確保安全性和有效性。監管機構的這種支持為公司開發和測試基於微生物組的療法提供了一個框架，使投資者對這些療法的潛在成功充滿信心。總體而言，對微生物組療法的興趣和資金的增加正在推動更多的研究和開發工作。這將有助於更好地了解人類微生物組，並開發出可以調節微生物組以改善人類健康的標靶療法。

微生物組治療市場根據類型、應用、最終用戶和地理位置進行分類。微生物組治療市場根據類型、應用和最終用戶進行分類。根據類型，微生物組治療市場分為治療方法和手術方法。根據應用，微生物組治療市場分為代謝紊亂和肥胖、艱難梭菌感染和發炎性腸道疾病。就最終用戶而言，微生物組治療市場分為醫院和診所、門診手術中心和家庭護理。

根據地理位置，市場分為北美、歐洲、亞太地區、中東和非洲以及南美洲和中美洲。北美在微生物組治療市場中佔有最大的市場佔有率。由於艱難梭菌病例的增加、技術的進步以及人們對腸道微生物群重要性的認知不斷提高，北美佔據了重要的市場佔有率。人們越來越了解人類微生物組在維持健康和預防疾病方面的重要性，這促使美國研究人員探索基於微生物組的干涉措施，作為治療各種疾病的一種有前景的方法。此外，該國在微生物組治療市場的主導地位主要歸因於其發達的研究基礎設施，有利於創新療法的開發此外，肥胖和炎症性腸道疾病等慢性病患病率的上升創造了對創新療法的需求治療，刺激微生物組療法的發展。基因定序和生物資訊學的技術進步使得微生物組的研究和改變成為可能，從而促進基於微生物組的個人化干涉措施的發展。個人化醫療的趨勢與客製化微生物組療法非常吻合。學術界、工業界和政府組織之間的合作也正在推動研究和開發工作，加速將科學發現轉化為商業產品。由於監管機構認知到微生物組療法的潛力並為其開發和批准提供指導，該領域的監管支持和投資進一步促進了市場成長。

對研究和創新的重視使人們對腸道微生物群對健康的影響有了深入的了解，為基於微生物組的治療奠定了堅實的基礎。加拿大生物技術和製藥的支持性監管環境鼓勵公司投資於以微生物組為重點的研究和開發。此外，創投和政府資助的增加也為這項研究注入了資金。 2020 年 1 月，加拿大政府及其合作夥伴投資 1,800 萬美元用於重要的微生物組研究。

加拿大人對腸道健康和微生物組在整體健康中的重要性的認知不斷提高，刺激了消費者對基於微生物組的產品的需求。此外，加拿大微生物組計劃 (CMI) 等措施的廣泛實施使得在加拿大與合作夥伴和利益相關者的合作變得更加容易。這使得將研究工作集中在微生物療法的開發上成為可能。學術機構、生技公司和醫療保健組織之間的合作和夥伴關係加速了研究和開發工作。此外，加拿大公司正在開拓國際市場，擴大微生物組療法的範圍。所有這些因素結合在一起表明微生物組療法在加拿大的前景光明。

ClinicalTrails.com、疾病管制與預防中心 (CDC) 以及食品藥物管理局 (FDA) 是在準備微生物組治療市場報告時參考的幾個關鍵的主要和次要來源。

目錄

第 1 章：簡介

  • Insight Partners 研究報告指南
  • 市場區隔

第 2 章：執行摘要

  • 微生物組治療市場（按地理位置）

第 3 章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：微生物組治療市場格局

  • 概述
  • PEST分析
    • 全球PEST分析

第 5 章：微生物組治療市場 - 主要產業動態

  • 市場促進因素：
    • 腸道微生物群在維持人類健康的潛力
    • 資金流入改善微生物組發現管道
  • 市場限制
    • 開發和生產成本高
  • 市場機會
    • 加強研發以更了解人類微生物組
  • 未來的趨勢
    • 人類微生物組治療的技術進步
  • 影響分析：

第 6 章：微生物組治療市場 - 全球市場分析

  • 微生物組治療市場收入，2020 - 2030

第 7 章：全球微生物組治療市場 - 2030 年收入與預測 - 按類型

  • 概述
  • 2022 年和 2030 年按類型分類的微生物組治療市場收入佔有率 (%)
  • 程式
  • 療法

第 8 章：全球微生物組治療市場 - 2030 年收入和預測 -按應用

  • 概述
  • 2022 年及 2030 年微生物組治療市場收入佔有率（按應用分類）（%）
  • 代謝紊亂與肥胖
  • C. 艱難梭菌感染 (CDI)
  • 發炎性腸道疾病
  • 其他

第 9 章：全球微生物組治療市場 - 收入和 2030 年預測 - 按最終用戶

  • 概述
  • 微生物組治療市場收入佔有率（按最終用戶），2022 年和 2030 年 (%)
  • 醫院和診所
  • 門診手術中心
  • 居家護理
  • 其他

第 10 章：微生物組治療市場 - 地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 中東非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第 11 章：微生物組治療市場 - 產業格局

  • 概述
  • 微生物組治療市場的成長策略
  • 無機成長策略
    • 概述
  • 有機成長策略
    • 概述

第 12 章：公司簡介

  • Enterome
  • Finch Therapeutics Group Inc
  • Caelus Health
  • Ferring Pharmaceuticals
  • Pendulum Therapeutics INC
  • AOBiome
  • Seres Therapeutics
  • Vedanta Biosciences
  • COST-BRY Pty Ltd (BiomeBank)
  • YSOPIA Bioscience

第 13 章：附錄

  • 關於我們
  • 專業術語
Product Code: TIPRE00027698

The microbiome therapeutics market is expected to grow from US$ 375.92 million in 2022 to US$ 813.38 million by 2030; it is anticipated to record a CAGR of 10.1% from 2022 to 2030.

The human microbiome includes all the microorganisms and their related metabolites/products identified in and around the human body. Technological advancement has enabled the examination of the pleiotropic effects of the human gut microbiome in maintaining health and diseases. With the extensive potential of microbes in human health, they hold enormous potential to be used as therapeutics for disease management. Microbiome therapy holds great promise to treat any severe type of disease condition and acts as the potential source to achieve the objective of personalized therapy by overcoming key issues like interpersonal variability and stability in every type of environment. Strategies such as fecal microbiota transplantation (FMT) or probiotics that rely on the administration of exogenous microbes could be used to manage dysbiosis-related disorders.

Potential of Gut Microbiota in Maintaining Human Health drives the growth the Microbiome Therapeutics Market

Microbiome therapeutics are aimed at modifying the gut microbiome by using bacteriophages, bacteriocins, antibiotics, native or synthetic bacteria, or subtractive or modulatory treatment. By offering individualized, harmonized, dependable, and long-lasting therapy, this strategy can overcome the limitations of traditional therapies. The global therapeutics market has demonstrated its enormous economic potential. Studies have shown promising results in using microbiome therapeutics for conditions such as inflammatory bowel disease, obesity, and even mental health disorders. Ongoing research is also exploring the potential of microbiome-based interventions in areas of cancer treatment, diabetes management, and cardiovascular health. Further, the incidence of gastrointestinal illnesses increases with age, and the GI Alliance data from February 2021 estimates that almost 20 million Americans have chronic digestive diseases, and over 62 million Americans receive a diagnosis of gastrointestinal diseases each year. The International Foundation for Gastrointestinal Disorders, Inc. (IFFGD) released statistics showing that GERD prevalence ranges from 18% to 28% in North America, 23% in South America, and 9-26% in Europe. Therefore, in the upcoming years, the increasing frequency of gastrointestinal disorders will fuel the market expansion.

By understanding the intricate relationship between microbiome and disease development, scientists are developing personalized treatments that target the root cause of the problem rather than merely managing symptoms. As knowledge expands and technologies advance, microbiome therapeutics have the potential to become a cornerstone of modern medicine, offering hope for improved health outcomes for individuals affected by a range of diseases.

The growing recognition of the microbiome's importance in human health and disease has encouraged rigorous research and development efforts to further understand the human microbiome and develop microbiome therapeutics. It has helped develop potential therapeutics and identify hindrances. Advancements in technology and research tools have also contributed to growing R&D. Next-generation sequencing and metagenomic analysis have allowed for a more comprehensive and detailed study of the microbiome. These tools enable researchers to identify specific microbial species and their functions, as well as track changes in the microbiome over time. Regulatory agencies, such as the FDA, are also supporting R&D efforts in the field of microbiome therapeutics. The FDA has established guidelines for FMT and has developed interest in advancing the field through regulatory pathways to ensure safety and efficacy. This support from regulatory agencies provides a framework for companies to develop and test microbiome-based therapies, giving investors confidence in the potential success of these treatments. Overall, the increased interest and funding in microbiome therapeutics are driving more research and development efforts. This will lead to a better understanding of the human microbiome and the development of targeted therapies that can modulate the microbiome to improve human health.

The microbiome therapeutics market is divided on the basis of type, application, end user, and geography. The microbiome therapeutics market is divided on the basis of type, application, and end user. Based on type, the microbiome therapeutics market is segmented into therapeutics and procedures. By application, the microbiome therapeutics market is segmented into metabolic disorders and obesity, C. difficile infection, and inflammatory bowel diseases. In terms of end users, the microbiome therapeutics market is classified as hospitals and clinics, ambulatory surgery centers, and home care.

Based on geography, the market is segmented into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America held the largest market share of the microbiome therapeutics market. North America accounts for a significant market share owing to the growing incidences of C. difficile cases, technological advances, and growing awareness about the importance of gut microbiota. The increasing understanding of the importance of the human microbiome in maintaining health and preventing diseases has led researchers in the US to explore microbiome-based interventions as a promising approach to treat various conditions. Additionally, the dominance of this country in the microbiome therapeutics market is mainly attributed to its well-developed research infrastructure that favors the development of innovative treatments Further, the rising prevalence of chronic diseases such as obesity and inflammatory bowel disease has created a demand for innovative treatments, spurring the development of microbiome therapeutics. Technological advancements in gene sequencing and bioinformatics enable the study and alteration of the microbiome, facilitating the development of personalized microbiome-based interventions. The trend toward personalized medicine aligns well with tailormade microbiome therapeutics. Collaborations between academia, industry, and government organizations are also fueling research and development efforts, accelerating the translation of scientific discoveries into commercial products. Regulatory support and investment in the field further contribute to market growth, as regulatory bodies recognize the potential of microbiome therapeutics and provide guidance for their development and approval.

An emphasis on research and innovation has yielded a significant understanding of the impact of gut microbiota on health, providing a solid foundation for microbiome-based therapeutics. A supportive regulatory environment for biotechnology and pharmaceuticals in Canada has encouraged companies to invest in microbiome-focused research and development. Additionally, increased venture capital investments and government funding have infused capital into this research. In January 2020, the Government of Canada, along with its partners, invested US$ 18 million in crucial microbiome research.

The rising awareness among Canadians about the importance of gut health and microbiome in overall well-being has spurred consumer demand for microbiome-based products. Moreover, the widespread implementation of initiatives such as the Canadian Microbiome Initiative (CMI) makes working with partners and stakeholders easier in Canada. This makes it possible to concentrate research efforts on the development of microbiome therapies. Collaborations and partnerships between academic institutions, biotechnology firms, and healthcare organizations have accelerated research and development efforts. Moreover, Canadian companies are exploring international markets, expanding the reach of microbiome therapeutics. All these factors combined indicate a promising trajectory for microbiome therapeutics in Canada.

ClinicalTrails.com, Centers for Disease Control and Prevention (CDC), and Food and Drug Administration (FDA), are a few key primary and secondary sources referred to while preparing the report on the microbiome therapeutics market.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the microbiome therapeutics market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the microbiome therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth market trends and outlook coupled with the factors driving the microbiome therapeutics market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Microbiome Therapeutics Market, by Geography

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Microbiome Therapeutics Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
    • 4.2.1 Global PEST Analysis

5. Microbiome Therapeutics Market - Key Industry Dynamics

  • 5.1 Market Drivers:
    • 5.1.1 Potential of Gut Microbiota in Maintaining Human Health
    • 5.1.2 Inflow of Funds to Ameliorate Microbiome Discovery Pipeline
  • 5.2 Market Restraints
    • 5.2.1 High Cost of Development and Production
  • 5.3 Market Opportunities
    • 5.3.1 Increasing R&D to Gain Better Understanding of Human Microbiome
  • 5.4 Future Trends
    • 5.4.1 Technological Advancement in Human Microbiome Therapeutics
  • 5.5 Impact Analysis:

6. Microbiome Therapeutics Market - Global Market Analysis

  • 6.1 Microbiome Therapeutics Market Revenue (US$ Mn), 2020 - 2030

7. Global Microbiome Therapeutics Market - Revenue and Forecast to 2030 - by Type

  • 7.1 Overview
  • 7.2 Microbiome Therapeutics Market Revenue Share, by Type, 2022 & 2030 (%)
  • 7.3 Procedure
    • 7.3.1 Overview
    • 7.3.2 Procedure: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Therapeutics
    • 7.4.1 Overview
    • 7.4.2 Therapeutics: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
      • 7.4.2.1 Global: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)

8. Global Microbiome Therapeutics Market - Revenue and Forecast to 2030 - by Application

  • 8.1 Overview
  • 8.2 Microbiome Therapeutics Market Revenue Share, by Application, 2022 & 2030 (%)
  • 8.3 Metabolic Disorder and Obesity
    • 8.3.1 Overview
    • 8.3.2 Metabolic Disorder and Obesity: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 C. Difficile Infection (CDI)
    • 8.4.1 Overview
    • 8.4.2 C. Difficile Infection (CDI): Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Inflammatory Bowel Disease
    • 8.5.1 Overview
    • 8.5.2 Inflammatory Bowel Disease: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.6 Others
    • 8.6.1 Overview
    • 8.6.2 Others: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

9. Global Microbiome Therapeutics Market - Revenue and Forecast to 2030 - by End User

  • 9.1 Overview
  • 9.2 Microbiome Therapeutics Market Revenue Share, by End User, 2022 & 2030 (%)
  • 9.3 Hospitals and Clinics
    • 9.3.1 Overview
    • 9.3.2 Hospitals and Clinics: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Ambulatory Surgical Centers
    • 9.4.1 Overview
    • 9.4.2 Ambulatory Surgical Centers: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.5 Homecare
    • 9.5.1 Overview
    • 9.5.2 Homecare: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.6 Others
    • 9.6.1 Overview
    • 9.6.2 Others: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)

10. Microbiome Therapeutics Market - Geographical Analysis

  • 10.1 North America Microbiome Therapeutics Market, Revenue and Forecast To 2030
    • 10.1.1 Overview
    • 10.1.2 North America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.1.3 North America: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.1.3.1 North America: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    • 10.1.4 North America: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    • 10.1.5 North America: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
    • 10.1.6 North America Microbiome Therapeutics Market, by Country
      • 10.1.6.1 US
        • 10.1.6.1.1 Overview
        • 10.1.6.1.2 US Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.6.1.3 US: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.1.6.1.3.1 US: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.1.6.1.4 US: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.1.6.1.5 US: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.1.6.2 Canada
        • 10.1.6.2.1 Overview
        • 10.1.6.2.2 Canada Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.6.2.3 Canada: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.1.6.2.3.1 Canada: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.1.6.2.4 Canada: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.1.6.2.5 Canada: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.1.6.3 Mexico
        • 10.1.6.3.1 Overview
        • 10.1.6.3.2 Mexico Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.1.6.3.3 Mexico: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.1.6.3.3.1 Mexico: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.1.6.3.4 Mexico: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.1.6.3.5 Mexico: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  • 10.2 Europe Microbiome Therapeutics Market, Revenue and Forecast to 2030
    • 10.2.1 Overview
    • 10.2.2 Europe Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.2.3 Europe: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.2.3.1 Europe: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    • 10.2.4 Europe: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    • 10.2.5 Europe: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
    • 10.2.6 Europe Microbiome Therapeutics Market, by Country
      • 10.2.6.1 UK
        • 10.2.6.1.1 Overview
        • 10.2.6.1.2 UK Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.1.3 UK: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.2.6.1.3.1 UK: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.2.6.1.4 UK: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.2.6.1.5 UK: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.2.6.2 Germany
        • 10.2.6.2.1 Overview
        • 10.2.6.2.2 Germany Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.2.3 Germany: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.2.6.2.3.1 Germany: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.2.6.2.4 Germany: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.2.6.2.5 Germany: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.2.6.3 France
        • 10.2.6.3.1 Overview
        • 10.2.6.3.2 France Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.3.3 France: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.2.6.3.3.1 France: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.2.6.3.4 France: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.2.6.3.5 France: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.2.6.4 Italy
        • 10.2.6.4.1 Overview
        • 10.2.6.4.2 Italy Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.4.3 Italy: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.2.6.4.3.1 Italy: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.2.6.4.4 Italy: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.2.6.4.5 Italy: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.2.6.5 Spain
        • 10.2.6.5.1 Overview
        • 10.2.6.5.2 Spain Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.5.3 Spain: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.2.6.5.3.1 Spain: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.2.6.5.4 Spain: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.2.6.5.5 Spain: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.2.6.7 Rest of Europe
        • 10.2.6.7.1 Overview
        • 10.2.6.7.2 Rest of Europe Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.2.6.7.3 Rest of Europe: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.2.6.7.3.1 Rest of Europe: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.2.6.7.4 Rest of Europe: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.2.6.7.5 Rest of Europe: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  • 10.3 Asia Pacific Microbiome Therapeutics Market, Revenue and Forecast to 2030
    • 10.3.1 Overview
    • 10.3.2 Asia Pacific Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.3.3 Asia Pacific: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.3.3.1 Asia Pacific: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    • 10.3.4 Asia Pacific: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    • 10.3.5 Asia Pacific: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
    • 10.3.6 Asia Pacific Microbiome Therapeutics Market, by Country
      • 10.3.6.1 China
        • 10.3.6.1.1 Overview
        • 10.3.6.1.2 China Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.1.3 China: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.3.6.1.3.1 China: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.3.6.1.4 China: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.3.6.1.5 China: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.3.6.2 Japan
        • 10.3.6.2.1 Overview
        • 10.3.6.2.2 Japan Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.2.3 Japan: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.3.6.2.3.1 Japan: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.3.6.2.4 Japan: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.3.6.2.5 Japan: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.3.6.3 India
        • 10.3.6.3.1 Overview
        • 10.3.6.3.2 India Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.3.3 India: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.3.6.3.3.1 India: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.3.6.3.4 India: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.3.6.3.5 India: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.3.6.4 Australia
        • 10.3.6.4.1 Overview
        • 10.3.6.4.2 Australia Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.4.3 Australia: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.3.6.4.3.1 Australia: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.3.6.4.4 Australia: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.3.6.4.5 Australia: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.3.6.5 South Korea
        • 10.3.6.5.1 Overview
        • 10.3.6.5.2 South Korea Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.5.3 South Korea: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.3.6.5.3.1 South Korea: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.3.6.5.4 South Korea: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.3.6.5.5 South Korea: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.3.6.7 Rest of Asia Pacific
        • 10.3.6.7.1 Overview
        • 10.3.6.7.2 Rest of Asia Pacific Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.3.6.7.3 Rest of Asia Pacific: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.3.6.7.3.1 Rest of Asia Pacific: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.3.6.7.4 Rest of Asia Pacific: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.3.6.7.5 Rest of Asia Pacific: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  • 10.4 Middle East & Africa Microbiome Therapeutics Market, Revenue and Forecast to 2030
    • 10.4.1 Overview
    • 10.4.2 Middle East & Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.4.3 Middle East & Africa: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.4.3.1 Middle East & Africa: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    • 10.4.4 Middle East & Africa: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    • 10.4.5 Middle East & Africa: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.4.5.1 Middle East & Africa Microbiome Therapeutics Market, by Country
      • 10.4.5.2 Saudi Arabia
        • 10.4.5.2.1 Overview
        • 10.4.5.2.2 Saudi Arabia Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.4.5.2.3 Saudi Arabia: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.4.5.2.3.1 Saudi Arabia: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.4.5.2.4 Saudi Arabia: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.4.5.2.5 Saudi Arabia: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.4.5.3 South Africa
        • 10.4.5.3.1 Overview
        • 10.4.5.3.2 South Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.4.5.3.3 South Africa: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.4.5.3.3.1 South Africa: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.4.5.3.4 South Africa: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.4.5.3.5 South Africa: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.4.5.4 UAE
        • 10.4.5.4.1 Overview
        • 10.4.5.4.2 UAE Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.4.5.4.3 UAE: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.4.5.4.3.1 UAE: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.4.5.4.4 UAE: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.4.5.4.5 UAE: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.4.5.5 Rest of Middle East Africa
        • 10.4.5.5.1 Overview
        • 10.4.5.5.2 Rest of Middle East Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.4.5.5.3 Rest of Middle East Africa: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.4.5.5.3.1 Rest of Middle East Africa: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.4.5.5.4 Rest of Middle East Africa: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.4.5.5.5 Rest of Middle East Africa: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
  • 10.5 South & Central America Microbiome Therapeutics Market, Revenue and Forecast to 2030
    • 10.5.1 Overview
    • 10.5.2 South & Central America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
    • 10.5.3 South & Central America: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
      • 10.5.3.1 South & Central America: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
    • 10.5.4 South & Central America: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
    • 10.5.5 South & Central America: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
    • 10.5.6 South & Central America Microbiome Therapeutics Market, by Country
      • 10.5.6.1 Brazil
        • 10.5.6.1.1 Overview
        • 10.5.6.1.2 Brazil Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.5.6.1.3 Brazil: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.5.6.1.3.1 Brazil: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.5.6.1.4 Brazil: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.5.6.1.5 Brazil: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.5.6.2 Argentina
        • 10.5.6.2.1 Overview
        • 10.5.6.2.2 Argentina Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.5.6.2.3 Argentina: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.5.6.2.3.1 Argentina: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.5.6.2.4 Argentina: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.5.6.2.5 Argentina: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)
      • 10.5.6.3 Rest of South & Central America
        • 10.5.6.3.1 Overview
        • 10.5.6.3.2 Rest of South & Central America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
        • 10.5.6.3.3 Rest of South & Central America: Microbiome Therapeutics Market, by Type, 2020-2030 (US$ Million)
        • 10.5.6.3.3.1 Rest of South & Central America: Microbiome Therapeutics Market, by Therapeutics, 2020-2030 (US$ Million)
        • 10.5.6.3.4 Rest of South & Central America: Microbiome Therapeutics Market, by Application, 2020-2030 (US$ Million)
        • 10.5.6.3.5 Rest of South & Central America: Microbiome Therapeutics Market, by End User, 2020-2030 (US$ Million)

11. Microbiome Therapeutics Market - Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in Microbiome Therapeutics Market
  • 11.3 Inorganic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Organic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Enterome
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Finch Therapeutics Group Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Caelus Health
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Ferring Pharmaceuticals
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Pendulum Therapeutics INC
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 AOBiome
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Seres Therapeutics
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Vedanta Biosciences
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 COST-BRY Pty Ltd (BiomeBank)
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 YSOPIA Bioscience
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About Us
  • 13.2 Glossary of Terms

List Of Tables

  • Table 1. Microbiome Therapeutics Market Segmentation
  • Table 2. Global Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
  • Table 3. North America Microbiome Therapeutics Market, by Type- Revenue and Forecast to 2030 (US$ Million)
  • Table 4. North America Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
  • Table 5. North America Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 6. North America Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 7. US Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 8. US Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
  • Table 9. US Microbiome Therapeutics Market, by Application- Revenue and Forecast to 2030 (US$ Million)
  • Table 10. US Microbiome Therapeutics Market, by End User- Revenue and Forecast to 2030 (US$ Million)
  • Table 11. Canada Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 12. Canada Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
  • Table 13. Canada Microbiome Therapeutics Market, by Application- Revenue and Forecast to 2030 (US$ Million)
  • Table 14. Canada Microbiome Therapeutics Market, by End User- Revenue and Forecast to 2030 (US$ Million)
  • Table 15. Mexico Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 16. Mexico Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
  • Table 17. Mexico Microbiome Therapeutics Market, by Application- Revenue and Forecast to 2030 (US$ Million)
  • Table 18. Mexico Microbiome Therapeutics Market, by End User- Revenue and Forecast to 2030 (US$ Million)
  • Table 19. Europe Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 20. Europe Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
  • Table 21. Europe Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 22. Europe Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 23. UK Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 24. UK Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
  • Table 25. UK Microbiome Therapeutics Market, by Application- Revenue and Forecast to 2030 (US$ Million)
  • Table 26. UK Microbiome Therapeutics Market, by End User- Revenue and Forecast to 2030 (US$ Million)
  • Table 27. Germany Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 28. Germany Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
  • Table 29. Germany Microbiome Therapeutics Market, by Application- Revenue and Forecast to 2030 (US$ Million)
  • Table 30. Germany Microbiome Therapeutics Market, by End User- Revenue and Forecast to 2030 (US$ Million)
  • Table 31. France Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 32. France Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
  • Table 33. France Microbiome Therapeutics Market, by Application- Revenue and Forecast to 2030 (US$ Million)
  • Table 34. France Microbiome Therapeutics Market, by End User- Revenue and Forecast to 2030 (US$ Million)
  • Table 35. Italy Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 36. Italy Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
  • Table 37. Italy Microbiome Therapeutics Market, by Application- Revenue and Forecast to 2030 (US$ Million)
  • Table 38. Italy Microbiome Therapeutics Market, by End User- Revenue and Forecast to 2030 (US$ Million)
  • Table 39. Spain Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 40. Spain Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
  • Table 41. Spain Microbiome Therapeutics Market, by Application- Revenue and Forecast to 2030 (US$ Million)
  • Table 42. Spain Microbiome Therapeutics Market, by End User- Revenue and Forecast to 2030 (US$ Million)
  • Table 43. Rest of Europe Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 48. Rest of Europe Microbiome Therapeutics Market, by Therapeutics- Revenue and Forecast to 2030 (US$ Million)
  • Table 49. Rest of Europe Microbiome Therapeutics Market, by Application- Revenue and Forecast to 2030 (US$ Million)
  • Table 50. Rest of Europe Microbiome Therapeutics Market, by End User- Revenue and Forecast to 2030 (US$ Million)
  • Table 51. Asia Pacific Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 52. Asia Pacific Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 53. Asia Pacific Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 54. Asia Pacific Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 55. China Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 56. China Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 57. China Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 58. China Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 59. Japan Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 60. Japan Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 61. Japan Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 62. Japan Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 63. India Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 64. India Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 65. India Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 66. India Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 67. Australia Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 68. Australia Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 69. Australia Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 70. Australia Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 71. South Korea Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 72. South Korea Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 73. South Korea Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 74. South Korea Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 75. Rest of Asia Pacific Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 108. Rest of Asia Pacific Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 109. Rest of Asia Pacific Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 110. Rest of Asia Pacific Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 111. Middle East & Africa Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 112. Middle East & Africa Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 113. Middle East & Africa Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 114. Middle East & Africa Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 115. Saudi Arabia Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 116. Saudi Arabia Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 117. Saudi Arabia Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 118. Saudi Arabia Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 119. South Africa Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 120. South Africa Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 121. South Africa Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 122. South Africa Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 123. UAE Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 124. UAE Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 125. UAE Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 126. UAE Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 127. Rest of Middle East Africa Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 128. Rest of Middle East Africa Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 129. Rest of Middle East Africa Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 130. Rest of Middle East Africa Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 131. South & Central America Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 132. South & Central America Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 133. South & Central America Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 134. South & Central America Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 135. Brazil Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 136. Brazil Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 137. Brazil Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 138. Brazil Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 139. Argentina Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 140. Argentina Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 141. Argentina Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 142. Argentina Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 143. Rest of South & Central America Microbiome Therapeutics Market, by Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 144. Rest of South & Central America Microbiome Therapeutics Market, by Therapeutics - Revenue and Forecast to 2030 (US$ Million)
  • Table 145. Rest of South & Central America Microbiome Therapeutics Market, by Application - Revenue and Forecast to 2030 (US$ Million)
  • Table 146. Rest of South & Central America Microbiome Therapeutics Market, by End User - Revenue and Forecast to 2030 (US$ Million)
  • Table 147. Recent Inorganic Growth Strategies in the Microbiome Therapeutics Market
  • Table 148. Recent Organic Growth Strategies in Microbiome Therapeutics Market
  • Table 149. Glossary of Terms, Microbiome Therapeutics Market

List Of Figures

  • Figure 1. Microbiome Therapeutics Market Segmentation, By Geography
  • Figure 2. Global - PEST Analysis
  • Figure 3. Microbiome Therapeutics Market - Key Industry Dynamics
  • Figure 4. Impact Analysis of Drivers and Restraints
  • Figure 5. Microbiome Therapeutics Market Revenue (US$ Mn), 2020 - 2030
  • Figure 6. Microbiome Therapeutics Market Revenue, Geography (US$ Mn), 2022 - 2030
  • Figure 7. Microbiome Therapeutics Market Revenue Share, by Type, 2022 & 2030 (%)
  • Figure 8. Procedure: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Therapeutics: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Microbiome Therapeutics Market Revenue Share, by Application, 2022 & 2030 (%)
  • Figure 11. Metabolic Disorder and Obesity: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. C. Difficile Infection (CDI): Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Inflammatory Bowel Disease: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Otehrs: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Microbiome Therapeutics Market Revenue Share, End User, 2022 & 2030 (%)
  • Figure 16. Hospitals and Clinics: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Ambulatory Surgical Centers: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Homecare: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Others: Microbiome Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. North America: Microbiome Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 21. North America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 22. North America Microbiome Therapeutics Market, By Key Countries, 2022 and 2030 (%)
  • Figure 23. US Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 24. Canada Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 25. Mexico Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 26. Europe Microbiome Therapeutics Market, by Key Country - Revenue, 2022 (US$ Million)
  • Figure 27. Europe Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 28. Europe Microbiome Therapeutics Market, By Key Countries, 2022 and 2030 (%)
  • Figure 29. UK Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 30. Germany Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 31. France Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 32. Italy Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 33. Spain Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 34. Rest of Europe Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 36. Asia Pacific Microbiome Therapeutics Market, by Key Country - Revenue, 2022 (US$ Million)
  • Figure 37. Asia Pacific Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 38. Asia Pacific Microbiome Therapeutics Market, By Key Countries, 2022 and 2030 (%)
  • Figure 39. China Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 40. Japan Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 41. India Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 42. Australia Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 43. South Korea Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 44. Rest of Asia Pacific Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 53. Middle East & Africa Microbiome Therapeutics Market, by Key Country - Revenue, 2022 (US$ Million)
  • Figure 54. Middle East & Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 55. Middle East & Africa Microbiome Therapeutics Market, By Key Countries, 2022 and 2030 (%)
  • Figure 56. Saudi Arabia Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 57. South Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 58. UAE Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 59. Rest of Middle East Africa Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 60. South & Central America Microbiome Therapeutics Market, by Key Country - Revenue, 2022 (US$ Million)
  • Figure 61. South & Central America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 62. South & Central America Microbiome Therapeutics Market, By Key Countries, 2022 and 2030 (%)
  • Figure 63. Brazil Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 64. Argentina Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 65. Rest of South & Central America Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
  • Figure 66. Growth Strategies in Microbiome Therapeutics Market